| Literature DB >> 15551207 |
Robert B Belshe1, Frances K Newman, Edwin L Anderson, Peter F Wright, Ruth A Karron, Sharon Tollefson, Frederick W Henderson, H Cody Meissner, Shabir Madhi, Don Roberton, Helen Marshall, Richard Loh, Peter Sly, Brian Murphy, Joanne M Tatem, Valerie Randolph, Jill Hackell, William Gruber, Theodore F Tsai.
Abstract
We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6-18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15551207 DOI： 10.1086/425981
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226